Evaluation of a Beta-Blocker-Edema-Loop Diuretic Prescribing Cascade : A Prescription Sequence Symmetry Analysis
© The Author(s) 2022. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Drug-related adverse events associated with antihypertensive therapy may result in subsequent prescribing of other potentially harmful medications, known as prescribing cascades. The aim of this study was to assess the magnitude and characteristics of a beta-blocker-edema-loop diuretic prescribing cascade.
METHODS: A prescription sequence symmetry analysis was used to assess loop diuretic initiation before and after initiation of beta-blockers among patients 20 years or older without heart failure, atrial fibrillation, other arrythmias, or use of calcium channel blocker within a U.S. private insurance claims database (2005-2018). The temporality of loop diuretic initiation relative to a beta-blocker or negative control (renin-angiotensin system blocker) initiation was tabulated. Secular trend-adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) compared the initiation of loop diuretic 90 days before and after initiation of beta-blockers.
RESULTS: Among 988,675 beta-blocker initiators, 9,489 patients initiated a new loop diuretic prescription 90 days after and 5,245 patients before beta-blocker initiation, resulting in an aSR of 1.78 (95% CI, 1.72-1.84). An estimated 1.72 beta-blocker initiators per 100 patient-years experienced the prescribing cascade in the first 90 days. The aSR was disproportionately higher among older adults (aSR 1.97), men (aSR 2.25), and patients who initiated metoprolol tartrate (aSR 2.48), labetalol (aSR 2.18), or metoprolol succinate (aSR 2.11). Negative control results (aSR 1.09, 95% CI, 1.05-1.13) generally corroborated our findings, but suggested modest within-person time-varying confounding.
CONCLUSIONS: We observed excess use of loop diuretics following beta-blocker initiation that was only partially explained by secular trends or hypertension progression.
| Errataetall: |
CommentIn: Am J Hypertens. 2022 Jul 1;35(7):587-589. - PMID 35302582 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
American journal of hypertension - 35(2022), 7 vom: 01. Juli, Seite 601-609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vouri, Scott Martin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.07.2022 Date Revised 26.01.2023 published: Print CommentIn: Am J Hypertens. 2022 Jul 1;35(7):587-589. - PMID 35302582 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajh/hpac013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336401310 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336401310 | ||
| 003 | DE-627 | ||
| 005 | 20231225232048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajh/hpac013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336401310 | ||
| 035 | |a (NLM)35106529 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vouri, Scott Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a Beta-Blocker-Edema-Loop Diuretic Prescribing Cascade |b A Prescription Sequence Symmetry Analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2022 | ||
| 500 | |a Date Revised 26.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Am J Hypertens. 2022 Jul 1;35(7):587-589. - PMID 35302582 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Drug-related adverse events associated with antihypertensive therapy may result in subsequent prescribing of other potentially harmful medications, known as prescribing cascades. The aim of this study was to assess the magnitude and characteristics of a beta-blocker-edema-loop diuretic prescribing cascade | ||
| 520 | |a METHODS: A prescription sequence symmetry analysis was used to assess loop diuretic initiation before and after initiation of beta-blockers among patients 20 years or older without heart failure, atrial fibrillation, other arrythmias, or use of calcium channel blocker within a U.S. private insurance claims database (2005-2018). The temporality of loop diuretic initiation relative to a beta-blocker or negative control (renin-angiotensin system blocker) initiation was tabulated. Secular trend-adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) compared the initiation of loop diuretic 90 days before and after initiation of beta-blockers | ||
| 520 | |a RESULTS: Among 988,675 beta-blocker initiators, 9,489 patients initiated a new loop diuretic prescription 90 days after and 5,245 patients before beta-blocker initiation, resulting in an aSR of 1.78 (95% CI, 1.72-1.84). An estimated 1.72 beta-blocker initiators per 100 patient-years experienced the prescribing cascade in the first 90 days. The aSR was disproportionately higher among older adults (aSR 1.97), men (aSR 2.25), and patients who initiated metoprolol tartrate (aSR 2.48), labetalol (aSR 2.18), or metoprolol succinate (aSR 2.11). Negative control results (aSR 1.09, 95% CI, 1.05-1.13) generally corroborated our findings, but suggested modest within-person time-varying confounding | ||
| 520 | |a CONCLUSIONS: We observed excess use of loop diuretics following beta-blocker initiation that was only partially explained by secular trends or hypertension progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a beta-blockers | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a drug-induced adverse events | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a loop diuretics | |
| 650 | 4 | |a prescribing cascades | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 650 | 7 | |a Sodium Potassium Chloride Symporter Inhibitors |2 NLM | |
| 650 | 7 | |a Metoprolol |2 NLM | |
| 650 | 7 | |a GEB06NHM23 |2 NLM | |
| 700 | 1 | |a Morris, Earl J |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Hofer, Ann-Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Pepine, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Winterstein, Almut G |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Steven M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hypertension |d 1988 |g 35(2022), 7 vom: 01. Juli, Seite 601-609 |w (DE-627)NLM012611670 |x 1941-7225 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:7 |g day:01 |g month:07 |g pages:601-609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajh/hpac013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 7 |b 01 |c 07 |h 601-609 | ||